CLLS · Cellectis S.A.

Summary

Cellectis announced upcoming presentations of clinical data for lasme-cel and eti-cel at the EHA 2026 annual congress.

Key takeaways

• Phase 1 BALLI-01 data for lasme-cel in r/r B-ALL selected for oral presentation at EHA 2026.
• Lasme-cel showed promising safety and response rates in heavily pretreated patients.
• Pivotal Phase 2 BALLI-01 trial recruiting; interim data expected Q4 2026.
• Phase 1 NATHALI-01 data for eti-cel in r/r B-NHL accepted as poster presentation.
• Eti-cel preliminary analysis explores alemtuzumab exposure and CAR-T expansion.
• Phase 1 NATHALI-01 clinical data planned for disclosure in Q4 2026.